|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
173,744,000 |
Market
Cap: |
1.41(B) |
Last
Volume: |
148,509 |
Avg
Vol: |
0 |
52
Week Range: |
$7.6 - $15.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.3 |
Insider 6 Months : 8.3 |
Insider 3/6 Months : 16.7 |
|
Guru Rank Number : 607 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
Total People Bought |
2 |
2 |
2 |
2 |
Total Buy Transactions |
2 |
2 |
3 |
3 |
Total Shares Sold |
280,916 |
294,129 |
403,559 |
1,047,483 |
Total Sell Value |
$4,281,159 |
$4,424,082 |
$5,556,813 |
$12,970,668 |
Total People Sold |
5 |
6 |
6 |
9 |
Total Sell Transactions |
5 |
7 |
14 |
48 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sarissa Capital Management Lp |
10% Owner |
|
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,571 |
88,145 |
|
- |
|
Dreyfus Andrew |
Director |
|
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,571 |
151,639 |
|
- |
|
Currie Mark G |
Director |
|
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,571 |
591,758 |
|
- |
|
Duane Jon R |
Director |
|
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,571 |
91,758 |
|
- |
|
Shetzline Michael |
CMO,SVP,Head-Res&Drug |
|
2022-05-23 |
4 |
AS |
$11.50 |
$121,705 |
D/D |
(10,583) |
266,245 |
|
-9% |
|
Mccourt Thomas A |
Chief Executive Officer |
|
2022-05-23 |
4 |
AS |
$11.50 |
$417,542 |
D/D |
(36,308) |
798,881 |
|
-9% |
|
Rickard Jason |
SVP, Chief Operating Officer |
|
2022-05-23 |
4 |
AS |
$11.50 |
$155,676 |
D/D |
(13,537) |
404,074 |
|
-9% |
|
Silver Ronald |
Principal Accounting Officer |
|
2022-05-23 |
4 |
AS |
$11.50 |
$1,380 |
D/D |
(120) |
105,073 |
|
-9% |
|
Silver Ronald |
Principal Accounting Officer |
|
2022-03-24 |
4 |
AS |
$12.75 |
$38,645 |
D/D |
(3,031) |
105,193 |
|
-12% |
|
Moukheibir Catherine |
Director |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,466 |
77,779 |
|
- |
|
Sarissa Capital Management Lp |
10% Owner |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,152 |
66,574 |
|
- |
|
Mchugh Julie |
Director |
|
2022-03-14 |
4 |
AS |
$11.67 |
$233,400 |
D/D |
(20,000) |
118,373 |
|
1% |
|
Mccourt Thomas A |
Chief Executive Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
248,869 |
835,189 |
|
- |
|
Rickard Jason |
SVP, Chief Operating Officer |
|
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
90,498 |
417,611 |
|
- |
|
Shetzline Michael |
CMO,SVP,Head-Res&Drug |
|
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
81,448 |
276,828 |
|
- |
|
Silver Ronald |
Principal Accounting Officer |
|
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
47,013 |
108,224 |
|
- |
|
John Minardo |
Chief Legal Officer |
|
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
67,873 |
147,765 |
|
- |
|
Rickard Jason |
SVP, Chief Operating Officer |
|
2022-02-28 |
4 |
AS |
$10.77 |
$311,921 |
D/D |
(28,962) |
327,113 |
|
11% |
|
Silver Ronald |
Principal Accounting Officer |
|
2022-02-28 |
4 |
AS |
$10.77 |
$24,103 |
D/D |
(2,238) |
61,211 |
|
11% |
|
Mccourt Thomas A |
Chief Executive Officer |
|
2022-02-28 |
4 |
AS |
$10.77 |
$521,526 |
D/D |
(48,424) |
586,320 |
|
11% |
|
Shetzline Michael |
CMO,SVP,Head-Res&Drug |
|
2022-02-28 |
4 |
AS |
$10.77 |
$189,627 |
D/D |
(17,607) |
195,380 |
|
11% |
|
Rickard Jason |
SVP, Chief Operating Officer |
|
2022-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
36,174 |
356,075 |
|
- |
|
Mccourt Thomas A |
Chief Executive Officer |
|
2022-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
60,290 |
634,744 |
|
- |
|
Shetzline Michael |
CMO,SVP,Head-Res&Drug |
|
2022-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
29,326 |
212,987 |
|
- |
|
Mccourt Thomas A |
Chief Executive Officer |
|
2021-12-22 |
4 |
AS |
$11.41 |
$528,591 |
D/D |
(46,327) |
574,454 |
|
4% |
|
914 Records found
|
|
Page 5 of 37 |
|
|